5 Momentum Stocks to Buy for February Amid Volatility

In This Article:

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Despite fluctuations, the bull run continued in the first month of 2025. Market participants remained concerned about the Trump administration’s tariffs and trade-related policies and their impact on U.S. economic growth, especially on the inflation rate.

Moreover, a relatively hawkish statement by Fed Chairman Jerome Powell in a post-FOMC meeting in January regarding sticky inflation raised questions about the magnitude of interest rate cut this year. Additionally, prolonged geopolitical conflicts in the Middle-East and other parts of Asia and Europe pose concerns.

However, a handful of stocks are expected to maintain their momentum in February, too. Five such stocks with a favorable Zacks Rank are: Amphenol Corp. APH, Boston Scientific Corp. BSX, Annaly Capital Management Inc. NLY, Pinnacle Financial Partners Inc. PNFP and First Horizon Corp. FHN.

Top 5 Momentum Picks for January

These five stocks have strong potential for February and have seen positive earnings estimate revisions in the last seven days. Each of the stocks sports a Zacks Rank #1 (Strong Buy) at present and has a Zacks Momentum Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.

The chart below shows the price performance of our five picks in the past month.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Amphenol Corp.

Amphenol has been benefiting from a diversified business model. It expects first-quarter 2025 sales in the defense market to increase moderately on a sequential basis. APH’s strong portfolio of solutions, including high-technology interconnect products, is a key catalyst. Expanding spending on both current and next-generation defense technologies bodes well for APH’s top-line growth.

Apart from Defense, APH’s prospects ride on strong demand for its solutions across Commercial Air, Industrial and Mobile devices. For first-quarter 2025, Amphenol expects a mid-to-high single-digit range increase in Commercial Air sales. APH’s diversified business model lowers the volatility of individual end markets and geographies. Strong cash flow generating ability is noteworthy.

Amphenol has an expected revenue and earnings growth rate of 22.4% and 24.9%, respectively, for the current year. The Zacks Consensus Estimate for the current-year earnings has improved 1.7% over the last seven days.

Boston Scientific

Boston Scientific is seeing strength across target markets despite macroeconomic concerns, currency headwinds and related cost inflation. Strong worldwide demand for BSX’s MedSurg and Structural Heart lines, traction in United States and outside for its the next-generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers.